Navigation Links
Tailoring glioblastoma therapies: 1 size does not fit all
Date:2/6/2008

An upcoming G&D paper from Dr. Azad Bonni and colleagues at Harvard Medical School lends new insight into how the unique genetic signature of glioblastoma tumors affects treatment efficacy - a finding with promising hope for the therapeutic targeting of the leading cause of cancer-related deaths in the young and middle-aged population.

Dr. Bonni's group found that the transcription factor STAT3 has either a tumor promoting or tumor suppressive effect depending upon the genetic profile of the glioblastoma tumor.

Glioblastomas are the most common and aggressive type of adult brain cancer, with an annual incidence of approximately 13,000 in the United States, and an expected median survival rate of just over a year. STAT3 is a cytokine-activated transcription factor that has been previously reported to play a pro-oncogenic role in tumor development. Thus, much effort has been aimed at the development of STAT3 inhibitors as chemotherapeutic agents.

Dr. Bonni and colleagues now report that STAT3 can function as either a tumor suppressor or an oncoprotein. Using a mouse model system of two common genetic mutations in glioblastomas - PTEN deficiency or EGFRvIII activation -- the researchers show that PTEN regulates STAT3 tumor suppressor function, while STAT3 cooperates with the EGFRvIII oncoprotein to promote tumor growth.

Thus, the researchers convincingly demonstrate a need for effective therapies tailored to the unique genetic thumbprint of individual glioblastoma tumors. "These findings may change the way we approach not only glioblastoma but other types of cancer as well", says Azad Bonni, senior author of the study.


'/>"/>

Contact: Heather Cosel
coselpie@cshl.edu
Cold Spring Harbor Laboratory
Source:Eurekalert

Page: 1

Related medicine news :

1. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
2. A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ongoing effort ... has recently developed and published an informational resource that addresses frequently asked questions. ... common inquiries the site’s team of third party administrator (TPA) contributors regularly receives ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon ... is thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. ... SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is ...
(Date:3/28/2017)... ... 2017 , ... Oily skin is a common and unwelcomed occurrence in people of all ages, ... to offer to the discussion of dealing with excess skin oil. “Oily skin is a ... remedies that can help remove the oily shine while keeping the skin fresh and clean,” ...
(Date:3/27/2017)... Aurora, CO (PRWEB) , ... March 27, 2017 , ... ... Dr. Mark Braasch for leading sleep apnea treatment, with or without a referral. Sleep ... the condition, which can include daytime sleepiness, morning headaches and chronic snoring. , ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Akcea Therapeutics, a subsidiary ... to the company,s board of directors: ... Partners. Mr. Gabrieli will serve as chairman of the board ... former chief commercial officer of Forest Laboratories. ... Biolink Partners. "We are excited to ...
(Date:3/28/2017)... 28, 2017 RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Japan Patent Office (JPO) for the composition of ... (CTGF) for the treatment or prevention of fibrotic ... and proliferative retinopathy (Japanese Patent #: 6060071).  This ...
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, Inc., ... company, is pleased to announce that the Company ... of Panther Orthopedics, Inc., a San ... fixation solutions for orthopedic extremity applications.  ... expand rapidly, primarily due to procedure volume growth, ...
Breaking Medicine Technology: